Welcome to the iCAD Investors Page

iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy  solutions and services that enable clinicians to find and treat cancers earlier and  while enhancing patient care. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection (CAD) and radiation therapy (eBx) treatments.

The company's common stock is listed on the NASDAQ Stock Market under the symbol "ICAD".

Featured Financial Press Releases

Investor Relations

November 8, 2017
iCAD Reports Third Quarter 2017 Financial Results
Read More
View Webcast

November 1, 2017
iCAD To Report Third Quarter 2017 Financial Results On Wednesday, November 8
Read More
View Webcast

September 20, 2017
iCAD to Present at the Cantor Fitzgerald Global Healthcare Conference
Read More
View Webcast

August 8, 2017
iCAD Reports Second Quarter 2017 Financial Results And Announces $13 Million Credit Facility With Silicon Valley Bank
Read More
View Webcast

* See all Financial Press Releases

LifeSci Advisors

Bob Yedid,
646-597-6989

Bob@lifesciadvisors.com

Media Inquiries

ARPR, LLC
Erin Bocherer
855.300.8209 ext 120
erin@arpr.com

iCAD is committed to corporate sustainability and to making a difference for our environment.

Featured Events and Webcasts

© 2017, iCAD Inc.  All rights reserved.  iCAD, the iCAD logo and PowerLook are a trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.